pig without pigsiniti perform
lead candid next-gener enzym replac exocrin
pancreat insuffici condit respons signific morbid among
chronic pancreat us cystic fibrosi us popul
clinic develop remain believ advantag current product
could enabl becom epi treatment choic forecast sale
follow launch repres market share categori
low competit risk second candid develop infecti
diseas support care track enter clinic initi coverag
azrx outperform rate price target
epi us market innov long overdu digest
enzym defici hallmark epi continu address
replac crude pig-deriv enzym prepar poorli suit
human digest modest variabl activ correspondingli high
pill burden provid fertil opportun entrant offer clinic
clinic poc demonstr enter phase pilot phase
trial chronic pancreat pt produc clinic meaning increas
dietari fat absorpt per key cfa endpoint favorable/
consist trend metric observ safeti issu result
support upcom trial cystic fibrosi patient second major epi popul
properti make ideal fit view recombin yeast-
origin lipas featur sever key distinct current product includ high
activity/st low ph lack interfer bile salt resist
gut proteas although recent record pancreat enzym develop
mark disappoint believ well-posit
development commerci success
could mitig iv antibiot impact gut larg opportun
model patients/year risk iv abx-associ gi
syndrom lack prevent strategi result consider morbid
expens oral non-system enzym could offer meaning
protect preclin data support entri phase plan
lean organ favor cost structur azrx employe
cash burn enjoy net savings/credit
qualifi expenditur virtu french legaci particularli valuabl
yet rare benefit development-intens compani stand sever year
product revenu
treatment gastrointestin diseas
microbiom relat condit
analyst certif import disclosur see disclosur
approv launch epi
gener sale
believ uniqu profil lead candid
enabl displac current enzym replac product
pancreat insuffici enabl becom treatment
choic within market optimist
forecast sale follow launch
repres market share categori low
competit risk expect share outperform
initi phase trial cf
top-lin data phase cf
enter phase develop
sale higher vs forecast
demonstr clinic develop success begin
contribut valuat
fail pivot develop
gener sale estim
valu azrx share use risk-adjust discount cash flow analysi base case valuat obtain assign likelihood
commerci reach sale oper margin appli discount rate futur cash
flow assign termin valu
risk includ failur rais suffici cash complet clinic develop failur meet primari efficaci endpoint
pivot trial unexpect safeti issu relat aris failur delay gain fda approv
reason slower market adopt unexpect industri competit stock price volatil may heighten
due limit trade volum limit float
see azrx stock trade specul appropri risk toler investor
azrx lead candid next-gener enzym replac exocrin
pancreat insuffici market base product sale clinic
develop remain believ advantag current product could enabl
becom epi treatment choic forecast sale follow
launch repres market share categori low competit risk
second candid develop infecti diseas support care
like enter clinic initi coverag azrx outperform rate
price target
risk thesi
risk includ failur rais suffici cash complet clinic develop
failur meet primari efficaci endpoint pivot trial unexpect
safeti issu relat aris failur delay gain fda
approv reason slower market adopt unexpect industri
competit stock price volatil may heighten due limit trade
volum limit float
see azrx stock trade specul appropri risk
valu azrx share use risk-adjust discount cash flow analysi exhibit
valuat obtain assign likelihood
commerci reach sale oper
margin appli discount rate futur cash flow assign
less tax- less less chang net work capit free cash flow adj cash outstand share outstand per share discount analysi azurrx biopharma
azurrx inc azrx develop stage biopharmaceut compani focus
develop non-system recombin protein treatment gastrointestin
disord azrx two drug asset activ develop exhibit
azrx lead product candid recombin yeast-deriv lipas
develop treatment exocrin pancreat insuffici epi
syndrom common patient cystic fibrosi cf chronic pancreat
cp patient epi depend enzym supplement adequ
nutrient absorpt yet current product far optim associ
heavi pill burden next-gener product design
offer meaning patient advantag clinic proof-of-concept
recent demonstr phase trial forecast launch
achiev penetr peak translat
sale year
azrx second asset -lactamas prevent
nosocomi hospital-acquir infect asset current preclin
stage ind file anticip occur
diseas market overview
common caus exocrin pancreat insuffici chronic pancreat
cystic fibrosi also caus number condit
chronic pancreat condit affect individu signific
inflamm scar pancrea frequent harm destroy abil
produc digest enzym us preval cp
afflict cp exhibit epi
cystic fibrosi genet diseas caus mutat cftr gene
encod epitheli cell membran channel channel play signific role fluid
secret hydrat secret mucu disrupt lead product
thick/sticki mucu abnorm mucu basi issu affect lung
pancrea cf patient lung mucu respons obstruct
airway pancrea obstruct pancreat bile duct prevent
secret digest enzym cf patient suffer epi
epi impair product and/or deliveri digest enzym pancreat
origin small intestin result nutrient vitamin malabsorpt left untreat
dysfunct lead malnourish vitamin defici abdomin pain
well fat-laden foul-smel stool steatorrhea although pancrea suppli
three type enzym digest fat lipas protein proteas
carbohydr amylas bodi compens defici latter two
inabl properli digest fat hallmark epi strategi address
syndrom includ azrx focus lipas supplement
normal output threshold maintain normal fat absorpt indic
pancreass tremend reserv capac steatorrhea estim reach g/day
patient alcohol cp cf patient normal g/day
irrespect caus particular case epi treatment
enzym supplement taken conjunct meal current six pancreat
enzym replac therapi pert market aggreg defin
market us exhibit indic sizabl market epi treatment
use condit note ultresa viokac includ
data
compani present opco research
manag epi
treatment goal endpoint
epi treatment gener focus restor much possibl absorpt fat
protein sugar pancreat enzym replac therapi pert
mention earlier improv fat absorpt becom primari concern
reflect fda recognit coeffici fat absorpt cfa indirect
measur lipas activ primari endpoint product registr coeffici
nitrogen absorpt may also inform proteas activ
featur secondari endpoint histor develop campaign import
lipas replac proteas replac establish recent
research show lipas activ current therapi account
improv energi loss ingest food amylas replac
concern enzym abundantli made gland mouth
cystic fibrosi meaning benefit consid increas mean chang
cfa placebo patient baselin cfa per advisori
committe meet patient lesser improv cfa
expect accept guidelin
chronic pancreat patient gener less sick cf thu
typic requir dramat cfa increas meta-analysi pancreat enzym
replac therapi pert chronic pancreat exhibit cfa shown
averag mean chang pert placebo exclud visibl outlier
pari studi yield averag mean chang cfa placebo
importantli level chang cfa cp patient hold true creon alon
widely-us class creon shown caus mean chang
cfa placebo therefor assum cp patient meaning benefit
consid increas mean chang cfa placebo
exhibit meta-analysi pert studi
reduc fat loss improv absorpt issu
steatorrhea thought respons increas loss nitrogen
carbohydr due steric traffic jam caus lipid malabsorptionso reduc
steatorrhea reduc nitrogen loss access limit also respons
micronutri malabsorpt calcium iron selenium fat-solubl vitamin protein
carbohydr trap unabsorb fat reach colon stimul
anorect hormon reduc hunger increas malnutrit risk
also increas microbi flora metabol activ increas ga product
discomfort inhibit food intak
fda approv requir prescript pert
prior prescript pert use variou form sinc
centuri avail despit taken fda approv year
agenc issu requir manufactur prescript pert submit nda
maintain avail guidanc produc
requir subject enforc sinc
six pert product current fda-approv market us
creon pancreaz pertyz chiesi privat held ultresa aptali
privat held viokac aptali zenpep ergan contain porcine-deriv
pancreat enzym delayed-releas oral formul avoid destruct
pass stomach although head-to-head trial data avail
ab-rat bioequival interchang pharmaci
similar clinic efficaci safeti profil evid one product
superior anoth
current pert mediocr variabl potenc
avail porcine-deriv product provid compens epi
far optim consist adequ efficaci remain elus goal
establish step dose reliabl method gain
improv lead increas cost unnecessari safeti risk
import collect shortfal low enzymat activ human duodenum
fat princip digest reason ph-depend
enzym activ normal duoden ph mildli acid activ half
potenti becom wors ph becom acid happen
epi patient so-cal patholog ph sinc anoth function pancrea
secret bicarbon small intestin neutral acid inflow
stomach also acid duodenum precipit bile acid interfer
enzym action
guidelin treat epi result cf establish cystic
cff typic appli treatment epi result cp
well cff maintain mean dose lipas units/kg/m individu
assum averag individu epi kg treatment would
necessit units/m thu use creon meal would necessit nine small
pill unit capsul size four-fiv medium pill unit capsul size three
eat meal per day translat consider daili pill burden
impact quality-of-lif risk factor non-compli
histor develop campaign microbi enzymesaltu alnara
order improv epi treatment condit attempt recent year
develop product contain lipas deriv non-mammalian origin
visibl attempt bacteri lipas initi call trizytek altu re-nam solpura
alnara final sollpura anthera lipas becam interest due stabil
low ph stomach would elimin need enter coat
allow formul dri powder could dissolv water
altu perform four clinic trial cystic fibrosi patient shown exhibit
phase trial complet technic achiev statist signific upon
detail analysi strong geograph effect evid patient baselin
cfa mean differ group chang cfa
us ex-u ns patient overal group mean
differ group chang cfa us
ex-u ns per lacklust result specif regard patient outsid us
absenc suffici cash compani decid termin program
led asset transfer sever hand includ alnara
solpura anthera sollpura
exhibit altuss develop trizytek
altu file opco research
alnara decid solpura still potenti ran two clinic studi cf patient dose-
rang trial call pivot trial call result
trial statistically-signific seen exhibit lead alnara submit
nda howev solpura caus lower improv cfa approv
porcine-deriv therapi seen exhibit basi advisori
committe meet conclud effect candid
shown nda receiv later year
exhibit clinic trial solpura lipromatas
exhibit chang cfa studi
exhibit cross-studi comparison chang cfa result
despit alnara debacl anthera licens drug belief hope remain
bacteri deriv lipas call sollpura anthera ran phase trial
miss primari endpoint narrow margin second phase follow
fail howev put entir program end april
consist recombin lipas deriv yeast strain yarrowia
lipolytica oleagin relat oil varieti degrad live carbon
sourc hydrocarbon fatti acid fat oil virtu metabol
pathway abl thrive harsh condit enzym fact
evalu use industri bioengin applic
azrx develop treatment epi goal provid better
solut current product demonstr data exhibit
featur high peak lipolyt activ robust activ patholog ph
duodenum thu allow enzym near potenti peak lipolyt activ ph
level relev fat digest stabil low ph level prevent
degrad low ph stomach data also show superior
recombin dog gastric lipas rdgl recombin human pancreat lipas
exhibit superior variou ph level
aloul et al gastroenterolog compani present opco research
azrx believ may enabl epi patient reduc medic intak
capsul three-four smaller capsul per meal exhibit current
formul howev azrx believ suffici room optim
formul potenti reduc dose two pill per meal
exhibit pill burden creon vs current formul
date azrx complet one clinic studi phase trial
patient epi although trial enrol cp patient effect serv
phase cf develop
design phase trial multicent open-label studi investig
escal dose cp patient total durat treatment
day follow step-up dose schedul follow two-week washout period
final exhibit primari endpoint
safeti secondari endpoint efficaci measur cfa chang
exhibit design phase trial epi
compani present opco research
result azrx recent report posit top-lin data phase trial met
primari safeti secondari efficaci endpoint highest dose
spray dri show statist signific increas cfa
compar baselin mean increas though data trial
releas futur result illustr dose-depend
disclos exhibit importantli result demonstr abl
improv mean cfa slightli histor benchmark cp
patient moreov achiev result dose low rel
mass porcine-deriv pert typic need achiev level
exhibit dose-depend efficaci cfa
compani present opco research
azrx recent announc fda clear ind phase active-
compar efficaci trial cf patient epi expect begin enrol
ye trial conduct site us eu patient
enrol phase featur crossov design patient serv his/her
control two treatment phase standard-of-car
run three week primari endpoint chang cfa baselin
assum posit result compani would perform phase registr trial
cp patient believ azrx could posit file nda potenti
approv launch
ip
azrx hold exclus right north america south america exclud
brazil asia exclud china japan australia new zealand israel
licens agreement laboratoir mayoli spindler sa
pursuant agreement azrx oblig pay third-parti mileston
payment upon fda approv royalti net sale
royalti net sale
azrx patent coverag potenti extens
patent contain claim method non-homolog transform
yarrowia lipolytica clone express acid-resist extracellular lipas
yarrowia lipolyica method produc lipas transform yarrowia lipolyica
cell capabl produc said lipas use though patent expir late
assum extens grant fda give year exclus date
approv novel biolog would last assum approv
azrx second asset -lactamas develop oral
formul prevent nosocomi hospital-acquir infect
caus clostridium difficil vancomycin-resist enterococcu vre unlik
candid origin entir in-hous effort
epi market model market y/i growth sale mm sourc compani inform oppenheim estim azrx outperform
normal condit gut maintain divers microb kept
balanc howev antibiot skew distribut indiscrimin action
gi flora result patient may encount condit certain bacteria
abl prolifer unoppos due microorgan absenc potenti lead
clinic syndrom demand anti-microbi therapi
design protect gi bacteri popul therefor support intestin
health inactiv antibiot molecul enter gi tract
system absorb co-administ antibiot azrx focus iv
commonli use within hospit expect interfer
abil fight primari infect
compani recent report posit preclin result expect file
ind prophylact treatment current approv difficil
common caus antibotic-rel diarrhea product potenti wide
use among million patient year receiv iv -lactam antibiot
synthet biolog syn current develop enzym ribaxamas
prevent nosocomi antibiotic-rel infect syn complet phase trial
prevent diff ribaxamas shown reduc rel risk
patient accord syn candid phase readi
howev awar forward develop plan
mr spoor previous presid chief execut offic member board
director fluoropharma medic inc februari decemb
mr spoor cfo sunston bioscienc nanotechnolog firm
strategi consult oliv wyman work biotechnolog pharmaceut medic
devic health insur compani mr spoor equiti research analyst
morgan credit suiss cover biotechnolog medic devic industri prior
career wall street mr spoor work pharmaceut industri spend
year amersham /ge healthcar work seven countri varieti
commerci strategi role mr spoor hold pharmaci degre univers
toronto well columbia univers concentr financ
mr shenouda year experi pharmaceut secur
industri recent mr shenouda head busi develop
licens inc prior serv head east coast oper
blueprint life scienc group strateg investor relat consult mr shenouda
spent bulk career equiti analyst senior level posit stifel
nicolau ub jp morgan cover broad rang small larg cap
biotechnolog compani mr shenouda start sell-sid career
bear stearn coverag univers focus us european pharmaceut
compani enter wall street mr shenouda manag consult
pricewaterhousecoop pharmaceut consult practic also spent time
pharmaceut sale work hospit repres manag care
specialist pharmaceut product divis mr shenouda
earn bs pharmaci st john univers regist pharmacist new
jersey california also receiv rutger univers graduat school
manag
prior join azurrx dr pennington spent eleven year
chief medic offic senior clinic fellow held senior medic
posit number biopharmaceut compani includ intermun cotherix
dr pennington led registr effort twelv success
bla/nda submiss anoth ten europ asia prior join
biotech industri dr pennington spent ten year medic faculti harvard
medic school dr pennington receiv medic degre univers
oregon health scienc universari board intern medicin infecti
stock price compani mention report
mm except per share data fy sales- total revenues- y/i growth cogs- sale protea group- gross income- gross margin expens sale expens sale expens total oper oper oper marginnainterest pre-tax incom tax benefit expens tax rate incom sale gaap dilut share azurrx biopharma
mm except per share data fy incom flow net cash use issuanc common net cash use net chang effect exchang rate chang equival cash equival restrict cash mm except per share data fy total current properti equip leasehold improv total total current conting total subscript common addit paid-in retatin accumul comprehens total sharehold total liabil sharehold azrx outperform
